Current preclinical models for the advancement of translational bladder cancer research

David J. DeGraff, Victoria L. Robinson, Jay B. Shah, William D. Brandt, Guru Sonpavde, Yibin Kang, Monica Liebert, Xue Ru Wu, John A. Taylor

Research output: Contribution to journalReview article

15 Scopus citations

Abstract

Bladder cancer is a common disease representing the fifth most diagnosed solid tumor in the United States. Despite this, advances in our understanding of the molecular etiology and treatment of bladder cancer have been relatively lacking. This is especially apparent when recent advances in other cancers, such as breast and prostate, are taken into consideration. The field of bladder cancer research is ready and poised for a series of paradigm-shifting discoveries that will greatly impact the way this disease is clinically managed. Future preclinical discoveries with translational potential will require investigators to take full advantage of recent advances in molecular and animal modeling methodologies. We present an overview of current preclinical models and their potential roles in advancing our understanding of this deadly disease and for advancing care.

Original languageEnglish (US)
Pages (from-to)121-130
Number of pages10
JournalMolecular cancer therapeutics
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1 2013

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

DeGraff, D. J., Robinson, V. L., Shah, J. B., Brandt, W. D., Sonpavde, G., Kang, Y., ... Taylor, J. A. (2013). Current preclinical models for the advancement of translational bladder cancer research. Molecular cancer therapeutics, 12(2), 121-130. https://doi.org/10.1158/1535-7163.MCT-12-0508